Seasonality, mass vaccination and critical policy evaluation on global exit strategy of COVID-19 crisis
There is a strong coordinated effort by vaccination groups all over the world to put an end to the current crisis of COVID-19. Now sufficient data are…
Finland's epidemic 22 March 2024: the force driving up excess deaths continues to strengthen. In the past 12 months, the momentum — or 'torque' — of excess deaths among those under 25 has more than quadrupled. Strongest growth is seen among 5-9 year olds.1/x pic.twitter.com/vFWMH0cXPi— Ilkka Rauvola (@jukka235) March 22, 2024
Beau’s Lines and COVID-19; A Systematic Review on Their Association
Background: Beau’s lines are transverse grooves in the nail plate that result from transient interruption of the growth of the proximal nail matrix after severe disease. The aim of this study is to systematically report all evidence on the association of Beau’s lines with COVID-19 infection or vaccination against COVID-19. Methods: PubMed and Scopus databases were searched up to January 2024 for articles reporting Beau’s lines associated with COVID-19 infection or vaccination for COVID-19. PROSPERO ID: CRD42024496830. Results: PubMed search identified 299 records while Scopus search identified 18 records. After screening the bibliography, nine studies including 35 cases were included in our systematic review. The studies were reported from different areas around the world. Included studies documented Beau’s lines following COVID-19 vaccination (two studies) or after COVID-19 infection (seven studies). High variability was recorded in onset and resolution times among included cases, averaging 3 months and 6 months after COVID-19 infection, respectively. In the two studies reporting Beau’s lines after vaccination, onset was at 7 days and 6 weeks and resolution occurred after 8 and 17 weeks, respectively. Conclusions: To the best of our knowledge, this is the first systematic review reporting the association of Beau’s lines with COVID-19 infection and vaccination. Severe immune response can result in the formation of these nail disorders. Of importance, Beau’s lines represent a potential indicator of prior severe COVID-19 infection or vaccination for COVID-19, as well as a sign of long COVID-19 syndrome.
SARS-CoV-2 infection as a potential risk factor for the development of cancer
The COVID-19 pandemic has a significant impact on public health and the estimated number of excess deaths may be more than three times higher than documented in official statistics. Numerous studies have shown an increased risk of severe COVID-19 and ...
FIGURE 1The shared molecular mechanisms between SARS-CoV-2 oncogenesis.
Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness | The Journal of Infectious Diseases | Oxford Academic
Abstract. Background. Despite the availability of published data on 4 pandemics that have occurred over the past 120 years, there is little modern information o
Surgical Face Masks: No Statistically Significant Benefit Against COVID-19. Danish Study in Annals of Internal Medicine - Global ResearchGlobal Research - Centre for Research on Globalization
Most Western elites are telegraphing the message that we will be forced to cover our humanity with cheap face masks indefinitely. They are mandating that even two-year-olds must wear masks. The long-term effects on the lungs, emotional and behavioral problems, and development of infants and toddlers is enormous. For such an unconstitutional invasion of personal […]
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos | medRxiv
Introduction In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV-2 viral replication, but questions remained as to In-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. Methods We conducted a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy in RT - PCR proven COVID 19 positive patients. 62 patients were randomized to 3 treatment groups. (A) IV 6mg regime, (B)IV 12 mg regime (given Q84hrs for 2weeks) (C, control) L...
SARS-CoV-2 und Antihistaminika:„we found that the presence of histamine potentiated spike-mediated ACE2 internalization into endothelial cells. This effect was blocked by famotidine“Danke @FarazFallahi 👇🏻 https://t.co/p4F7nD1hyV— Dr. Isabelle Greber (@DrGreber) May 14, 2022
Wie immer nur stupide Impf-Propaganda!https://t.co/23Vf4MDkqmhttps://t.co/SCOXUG3aTShttps://t.co/GBFFAe03Z3https://t.co/e3jL4wJGU9https://t.co/zCdymEZb20https://t.co/WCKyJiGMRm— René (@Rhodan_77) July 24, 2022
Verdacht bestätigt: Das "Epizentrum" der Corona-Pandemie war tatsächlich der Fisch- und Tiermarkt von Wuhan, wie nun gleich zwei Studien belegen. Indizien
Is there a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality?
We primarily study a possible link between 2021 COVID-19 vaccination uptake in Europe and monthly 2022 excess all-cause mortality, i.e., mortality higher than before the pandemic. Analyses of 31 countries weighted by population size show that all-cause mortality during the first nine months of 2022 increased more the higher the 2021 vaccination uptake; a one percentage point increase in 2021 vaccination uptake was associated with a monthly mortality increase in 2022 by 0.105 percent (95% CI, 0.075-0.134). When controlling for alternative explanations, the association remained robust, and we discuss the result emphasizing causality as well as potential ecological fallacy. Also, the study shows that 2021 all-cause mortality was lower the higher the vaccination uptake, but this association became non-significant when controlling for alternative explanations.
IgG4 Antibodies Induced by mRNA Vaccines Generate Immune Tolerance to SARS-CoV-2’spike Protein by Suppressing the Immune System
Due to the health crisis caused by SARS-CoV-2, the creation of a new vaccine platform based on mRNA was implemented. Globally, around 13.32 billion COVID-19 vaccine doses of diverse platforms have been given, and up to this date, 69.7% of the total population received at least one injection of a COVID-19 vaccine. Although these vaccines prevent hospitalization and severe forms of the disease, increasing evidence has shown they do not produce sterilizing immunity, allowing people to suffer frequent re-infections. Recent research has also raised concerns that mRNA vaccines could induce immune tolerance, which, added to that caused by the virus itself, could complicate the clinical course of a COVID-19 infection. Furthermore, recent investigations have found high IgG4 levels in people who were administered two or more injections of mRNA vaccines. It has been suggested that an increase in IgG4 levels could have a protecting role by preventing immune over-activation, similar to that occurring during successful allergen-specific immunotherapy by inhibiting IgE-induced effects. Altogether, evidence suggests that the reported increase in the IgG4 levels detected after repeated vaccination with the mRNA vaccines is not a protective mechanism; rather, it may be a part of the immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses. IgG4-induced suppression of the immune system due to repeated vaccination can also cause autoimmune diseases, promotes cancer growth, and autoimmune myocarditis in susceptible individuals.
New study reveals alarming cardiovascular risks from COVID
The study published in Nature Cardiovascular Research reveals that SARS-CoV-2, the virus causing COVID-19, can directly infect coronary vessels and arterial plaques, heightening the risk of cardiovascular complications like heart attacks and strokes. These findings offer critical insights into the increased long-term cardiovascular risks for COVID-19 survivors and open new avenues for targeted therapies.
A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID‐19 patients
Journal of Medical Virology is a clinical virology journal focused on the diagnosis, epidemiology, immunology and pathogenesis of human viral infections & diseases.
Effect of COVID-19 vaccination and booster on maternal–fetal outcomes: a retrospective cohort study
COVID-19 in pregnant people increases the risk for poor maternal–fetal outcomes. However, COVID-19 vaccination hesitancy remains due to concerns over the vaccine’s potential effects on maternal–fetal outcomes. Here we examine the ...
We examined factors contributing to the transmission of an acute respiratory virus within multi-use facilities, focusing on an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a movie theater in the Republic of Korea.
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France
An economic evaluation was conducted to predict the economic and clinical burden of vaccinating immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines in Fall 2023 and Spring 2024 versus BNT162b2 variant-adapted vaccines in France. The number of symptomatic COVID-19 infections, hospitalizations, deaths, and long COVID cases, costs and quality-adjusted life years (QALYs) was estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) were based on real-world data from prior versions, suggesting higher protection against infection and hospitalization with mRNA-1273 vaccines. VE estimates were combined with COVID-19 incidence and probability of COVID-19 severe outcomes. Uncertainty surrounding VE, vaccine coverage, infection incidence, hospitalization and mortality rates, costs and QALYs were tested in sensitivity analyses. The mRNA-1273 variant-adapted vaccine is predicted to prevent an additional 3,882 infections, 357 hospitalizations, 81 deaths, and 326 long COVID cases when compared to BNT162b2 variant-adapted vaccines in 230,000 IC individuals. This translates to €10.1 million cost-savings from a societal perspective and 645 QALYs saved. Results were consistent across all analyses and most sensitive to variations surrounding VE and coverage. These findings highlight the importance of increasing vaccine coverage, and ability to induce higher levels of protection with mRNA-1273 formulations in this vulnerable population. ### Competing Interest Statement MK is a shareholder in Quadrant Health Economics, Inc., which was contracted by Moderna, Inc. to conduct this study. AL and MM are consultants at Quadrant Health Economics Inc. CD, NE and MU are employees of Moderna France and hold stock/stock options in the company. KJ and EB are employees of Moderna Inc and hold stock/stock options in the company. BD received fees for consultation from Moderna France. ### Funding Statement This study was funded by Moderna, Inc., Cambridge, MA, USA. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes
Seroprevalence and risk factors for SARS-CoV-2 infection in middle-sized cities of Burkina Faso: a descriptive cross-sectional study
Background Since March 2020, COVID-19 has evolved from a localized outbreak to a global pandemic. We assessed the seroprevalence of COVID-19 in three towns in the Centre Sud region of Burkina Faso. Methods A population-based cross-sectional survey was conducted in three medium-sized towns in Burkina Faso’s Centre Sud region, from June to July 2021. Subjects aged 16 or over at the time of the survey were considered for this seroprevalence study. The Biosynex COVID-19 BSS rapid test was used to detect immunoglobulin G (IgG) and immunoglobulin M (IgM) against SARS-CoV-2. A standardized questionnaire was also administered to collect additional information. Results A total of 2449 eligible participants (age ≥ 16 years) were identified. Serological tests for COVID-19 were performed in 2155 individuals. Finally, 2143 valid tests were retained and analyzed. Out of the entire sample, 246 positive tests were observed, corresponding to a prevalence of 11.48%. Prevalence was 9.35% (58 cases) in Kombissiri, 12.86% (80 cases) in Manga and 11.99% (108 cases) in Pô. By gender, 13.37% of women (164 cases) tested positive, and 8.95% of men (82 cases). Women accounted for 66.67% of all positive test subjects. The results show a significantly higher seroprevalence in women (P = 0.007), people over 55 years old (P = 0.004), overweight or obese people (P =0.026) and those with drinking water sources at home (0.013). Conclusions The results of this study show that the COVID-19 virus also circulates in the population of medium-sized towns in Burkina Faso, far more than is officially reported in the country. The study also highlighted the greater vulnerability of women to the epidemic, and the challenge of access to water in the face of diseases such as COVID-19. The preventive measures put in place to fight the pandemic must take these different factors into account. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was funded by ANRS MIE, an antonomous agency of Inserm, and by the French Development Agency (AFD). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Health Ethics Research Committee of the Ministry of Health of Burkina Faso gave approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors.
Effectiveness of interventions to reduce COVID-19 transmission in schools
School reopenings in 2021 and 2022 coincided with the rapid emergence of new SARS-CoV-2 variants in the United States. In-school mitigation efforts va…
SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19
Beckman et al. show that SARS-CoV-2 proteins are found in olfactory areas of the brains
of rhesus macaques at 7 days post infection. In addition to direct neuronal infection,
extensive neuroinflammation and vascular disruptions are observed, and these effects
are exacerbated in aged, diabetic animals.
%3Amax_bytes(150000)%3Astrip_icc()%3Afocal(554x339%3A556x341)%2Fcovid-mental-health-d0f1607a9b0440eb999b6301dd61c0f4.jpg?width=92&height=&ar=&mode=&format=avif&dpr=2)
